Skip to main content
SpringerLink
Log in

Correlation of pretreatment serum tissue polypeptide specific antigen (TPS) with prognosis in primary breast cancer

  • Published:
The Chinese-German Journal of Clinical Oncology

Abstract

Objective

The aim of this study was to explore the correlation of pretreatment serum tissue polypeptide specific antigen (TPS) with prognosis in primary breast cancer.

Methods

A total of 361 patients with grades I–III breast cancer had been followed up from January 2001 to February 2011. Serumal TPS level was measured by enzyme-linked immunosorbent assays (ELISA). Univariate and multivariate analyses were used to investigate associations between pretreatment TPS level and clinicopathological parameters and patient outcomes.

Results

First, at the univariate analysis, the expression of TPS was related with some clinicopathological traditional prognostic factors such as tumor size (P = 0.030), histologic grade (P = 0.001) and lymph node status (P = 0.008). Second, overall survival were significantly shorter among patients with elevated pretreatment serum TPS (P = 0.038). However, finally, multivariate Cox regression indicated that the level of pretreatment serum TPS was not an independent prognostic parameter for overall survival in primarily breast cancer patients (P > 0.05).

Conclusion

The expression of pretreatment serum TPS is closely correlated with clinicopathology parameters and overall survival of patients with primarily breast cancer, but its level has no independent prognostic value.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin, 2012, 62: 10–29.

    Article  PubMed  Google Scholar 

  2. Carison RW, Allred DC, Anderson BO, et al. NCCN Clinical Practice Guidelines in Oncology-Breast Cancer V1. 2012. National Comprehensive Cancer Network, 2012, January.

  3. Sturgeon CM, Duffy MJ, Stenman UH, et al. National Academy of Clinical Biochemistry Guidelines for the use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem, 2008, 54: e11–79.

    Article  PubMed  CAS  Google Scholar 

  4. Uehara M, Kinoshita T, Hojo T, et al. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA15-3) in breast cancer. Int J Clin Oncol, 2008, 13: 447–451.

    Article  PubMed  CAS  Google Scholar 

  5. Yerushalmi R, Tyldesley S, Kennecke H, et al. Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome. Ann Oncol, 2012, 23: 338–345.

    Article  PubMed  CAS  Google Scholar 

  6. Rydlander L, Ziegler E, Bergman T, et al. Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. Eur J Biochem, 1996, 241: 309–314.

    Article  PubMed  CAS  Google Scholar 

  7. Giai M, Roagna R, Ponzone R, et al. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients. Anticancer Res, 1996, 16: 875–881.

    PubMed  CAS  Google Scholar 

  8. Ahn SH, Yoo KY, The Korean Breast Cancer Society. Chronological changes of clinical characteristics in 31, 115 new breast cancer patients among Koreans during 1996–2004. Breast Cancer Res Treat, 2006, 99: 209–214.

    Article  PubMed  Google Scholar 

  9. Arciero C, Somiari SB, Shriver CD, et al. Functional relationship and gene ontology classification of breast cancer biomarkers. Int J Biol Markers, 2003, 18: 241–272.

    PubMed  CAS  Google Scholar 

  10. Xie XD, Zhang F, Zheng ZD, et al. The clinical significance of hMAM mRNA expression in peripheral blood of patients with breast cancer. Chinese-German J Clin Oncol, 2008, 7: 709–712.

    Article  CAS  Google Scholar 

  11. Sheard MA, Vojtesek B, Simickova M, et al. Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis. J Cell Biochem, 2002, 85: 670–677.

    Article  PubMed  CAS  Google Scholar 

  12. Schutte B, Henfling M, Kolgen W, et al. Keratin 8/18 breakdown and reorganization during apoptosis. Exp Cell Res, 2004, 297: 11–26.

    Article  PubMed  CAS  Google Scholar 

  13. Gion M, Borachi P, Dittadi R, et al. Quantitative measurement of soluble cytokeratin fragments in tissue cytosol of 599 node negative breast cancer patients: a prognostic marker possibly associated with apoptosis. Breast Cancer Res Treat, 2000, 59: 211–221.

    Article  PubMed  CAS  Google Scholar 

  14. Kit PJ, Goldschmidt HM, Wieggers BJ, et al. Tissue polypeptide specific antigen (TPS) determination before and during intermittent maximal androgen blockade in patients with metastatic prostatic carcinoma. Eur Urol, 2003, 43: 31–38.

    Article  Google Scholar 

  15. van Dalen A, Favier J, Burges A, et al. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients. Gynecol Oncol, 2000, 79: 444–450.

    Article  PubMed  Google Scholar 

  16. Nisman B, Amir G, Lafair J, et al. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer. Anticancer Res, 1999, 19: 3549–3552.

    PubMed  CAS  Google Scholar 

  17. Bremer K, Eklund G, Bjorklund B. Notable relationship between the level of tumor marker TPS in serum and survival in breast cancer. Anticancer Res, 1996, 16: 905–909.

    PubMed  CAS  Google Scholar 

  18. Hwa HL, Kuo WH, Chang LY, et al. Prediction of breast cancer and lymph node metastatic status with tumour markers using logistic regression models. J Eval Clin Pract, 2008, 14: 275–280.

    Article  PubMed  Google Scholar 

  19. Molina R, Barak V, van Dalen A, et al. Tumor Markers in Breast Cancer — European Group on Tumor Markers Recommendations. Tumor Biol, 2005, 26: 281–293.

    Article  Google Scholar 

  20. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol, 2007, 25: 5287–5312.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Laboratory Department, Laboratory of Biochemistry and Molecular Biology Research, Fujian Provincial, China

    Yuhong Zheng, Yan Chen, Minhua Hu, Yingying Lin & Yansong Chen

Authors
  1. Yuhong Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Minhua Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yingying Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yansong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yan Chen.

Additional information

Supported by a grant from the Youth Research of Health Department of Fujian Province.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zheng, Y., Chen, Y., Hu, M. et al. Correlation of pretreatment serum tissue polypeptide specific antigen (TPS) with prognosis in primary breast cancer. Chin. -Ger. J. Clin. Oncol. 11, 655–659 (2012). https://doi.org/10.1007/s10330-012-1060-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10330-012-1060-3

Key words

Search

Navigation